Fay W. Boozman College of Public Health UAMS – Doctoral Program

Fay W. Boozman College of Public Health
Image: publichealth.uams.edu

Before becoming an OB/GYN at Siloam Springs Women’s Center in Siloam Springs, Arkansas, Dr. Chad Hill attended the University of Arkansas in Fayetteville, Arkansas, where he earned a master of arts in microbiology and immunology. Dr. Chad Hill also earned his doctor of medicine while attending the University of Arkansas for Medical Sciences (UAMS), College of Medicine.

Combining clinical programs with research and education, the Fay W. Boozman College of Public Health at the University of Arkansas for Medical Sciences is dedicated to improving the well-being of Arkansas residents. The board of trustees for the University of Arkansas oversees the medical sciences department, and day-to-day operations are under the direction of the UAMS Chancellor.

The Fay W. Boozman College of Public Health doctoral program offers medical students the opportunity to earn a degree in specialized areas such as epidemiology, health systems research, and public health. The doctor of public health program includes subjects ranging from biostatistics and health behavior theory to public health law and management of healthcare organizations.

Advertisements

The Larry Gilstrap, MD, Fellowship for STD Prevention and Treatment

Larry Gilstrap, MD, Fellowship pic
Larry Gilstrap, MD, Fellowship
Image: cdcfoundation.org

An accomplished obstetrician and gynecologist, Dr. Chad Hill earned his doctor of medicine and master of arts in microbiology from the University of Arkansas in Fayetteville and serves as the director of Siloam Springs Women’s Center, where he is also the chief physician. Dr. Chad Hill is certified by the American Board of Obstetrics and Gynecology.

Treating sexually transmitted diseases (STDs) is an unfortunate but necessary reality that OB/GYNs have to deal with in modern medicine. That’s why the American Board of Obstetrics and Gynecology, in partnership with the Centers for Disease Control (CDC), is funding a fellowship that will help doctors become better prepared to prevent and treat STDs (especially HIV).

The three-year position was dubbed the Larry Gilstrap, MD, Fellowship and will see doctors work at the CDC for 12 months of the program. Both the American Board of Obstetrics and Gynecology and the CDC believe this fellowship will lead to greater awareness among physicians regarding advances in STD treatment and education, which will, in turn, be of great benefit to their patients.

When and How a LEEP Is Performed

 

Symptoms and Treatments of Uterine Fibroids

dr-chad-hill
Dr. Chad Hill
Image: siloamwomenscenter.com

Since 1998, Dr. Chad Hill has owned and operated the Siloam Springs Women’s Center in Siloam Springs, Arkansas. A practicing obstetrician and gynecologist at the clinic, Dr. Chad Hill has treated numerous cases of uterine fibroids.

More common than any other gynecological tumor, uterine fibroids affect 20 to 77 percent of women in their childbearing years. These numbers are so far apart because approximately 33 percent of fibroids are too small for physicians to detect in routine examinations, and many fibroids never cause symptoms.

Almost all fibroids are benign and do not increase a woman’s risk of developing cancer. Some fibroids, however, do cause significant pain and heavy or lengthy menstrual periods.

Uterine fibroids may also cause bleeding between periods, increased urinary frequency, and painful intercourse. For women whose fibroids are asymptomatic or minimally problematic, a physician may choose to watch the growths carefully and assess whether they will stop growing or shrink at menopause.

If symptoms are occasional, anti-inflammatory medications may be sufficient. If a patient is struggling with severe symptoms, however, the physician may choose to treat the fibroids with hormone-focused treatment or surgery.

Surgery may involve removal of the fibroids or of the uterus itself, depending on whether the patient wishes to have biological children. In some cases, a woman may be eligible for minimally invasive embolization of the fibroid, which interrupts blood supply and impedes tumor growth.